NEJM updates thyroid cancer management: what Canadian endocrinologists and patients need to know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A comprehensive review published June 18, 2026 in the New England Journal of Medicine (NEJM, Volume 394, Issue 23, pages 2340–2355) formalizes a risk-adapted framework for managing differentiated thyroid cancer (DTC), the most common form of thyroid malignancy, and explicitly endorses active surveillance as a legitimate first option for many low-risk papillary thyroid cancers. For Canadian patients, the review matters because it consolidates evidence that many people diagnosed with small, low-risk thyroid tumours may not need immediate surgery at all, a position that Canadian endocrinologists have been moving toward but that remains inconsistently applied across provinces.

Differentiated thyroid cancer includes papillary thyroid cancer and follicular thyroid cancer, both of which arise from thyroid follicular cells and together account for more than 90 percent of thyroid cancer diagnoses. The Canadian Cancer Society estimates roughly 9,000 Canadians are diagnosed with thyroid cancer each year, and the vast majority are DTC. The NEJM review, authored by Laszlo Hegedüs (Odense University Hospital, Denmark), Lori J. Wirth (Massachusetts General Hospital), and R. Michael Tuttle (Memorial Sloan Kettering Cancer Center), argues that risk stratification should be a continuous, dynamic process rather than a one-time staging exercise at diagnosis.

What this means in Canada

Health Canada has not issued a specific guidance document on thyroid cancer management protocols in response to this NEJM review, and the Society of Obstetricians and Gynaecologists of Canada (SOGC) does not hold a mandate over thyroid cancer. The relevant Canadian body is the Canadian Association of Nuclear Medicine and, more broadly, endocrinology divisions within provincial academic health centres. The Canadian Thyroid Association (CTA), which advises on clinical practice in Canada, has previously aligned with the American Thyroid Association (ATA) 2015 guidelines, which already introduced risk stratification. The NEJM 2026 review represents a further evolution of that thinking.

Molecular tumour profiling, which the NEJM review describes as a tool to refine risk beyond standard clinicopathological staging, is available at major Canadian cancer centres including Princess Margaret Cancer Centre (Toronto), the BC Cancer Agency (Vancouver), and the Jewish General Hospital (Montreal). However, access is not uniform. Patients in rural or northern communities, or in provinces without a dedicated thyroid oncology program, may face delays or referral barriers to molecular testing. The cost of molecular profiling panels is not consistently covered under provincial plans: Ontario's OHIP does not list thyroid molecular panel testing as a standard insured benefit, and coverage under Quebec's RAMQ and British Columbia's MSP depends on whether testing is ordered within a cancer centre context.

Targeted systemic therapies for advanced or radioiodine-refractory DTC include lenvatinib (sold in Canada as Lenvima, approved by Health Canada for DTC) and sorafenib (sold in Canada as Nexavar, also Health Canada-approved for DTC). Both are listed on some provincial formularies, but coverage is not automatic. In Ontario, Lenvima for thyroid cancer is reviewed through the Ontario Drug Benefit exceptional access program. Patients in provinces without robust exceptional access pathways may need to apply through the pan-Canadian Oncology Drug Review (pCODR) process or seek manufacturer compassionate access programs.

What changed

The NEJM review does not announce a single new drug or trial result. Instead, it consolidates a shift in clinical philosophy that has been building for roughly a decade. Three changes stand out.

First, active surveillance of low-risk papillary thyroid microcarcinomas (tumours 1 cm or smaller with no high-risk features) is now presented as a standard option, not a fringe one. Studies from Japan, the United States, and South Korea have tracked thousands of patients on surveillance protocols and found that the majority of these tumours do not grow meaningfully over years of follow-up. The review frames this as a genuine clinical choice to be made with the patient, not a default fallback.

Second, for low- and intermediate-risk DTC, the review supports minimalist surgical approaches, specifically hemithyroidectomy (removal of one thyroid lobe) rather than total thyroidectomy, and selective rather than routine use of radioiodine (iodine-131) ablation after surgery. This matters because total thyroidectomy requires lifelong levothyroxine (sold in Canada as Synthroid, Eltroxin, and generic levothyroxine) replacement and carries a small but real risk of hypoparathyroidism and recurrent laryngeal nerve injury. Avoiding unnecessary total thyroidectomy reduces those risks.

Third, for advanced DTC that no longer responds to radioiodine, the review maps out a systemic therapy sequence that incorporates molecular tumour characterization, specifically BRAF V600E mutation status and RET fusion status, to guide drug selection. BRAF-mutated tumours may respond to BRAF/MEK inhibitor combinations. RET-fusion-positive tumours may respond to selective RET inhibitors such as selpercatinib (sold in Canada as Retevmo, Health Canada-approved for RET-altered thyroid cancer).

What Canadian patients should know

If you have been diagnosed with a small papillary thyroid nodule or early-stage DTC, the NEJM review supports asking your endocrinologist or thyroid surgeon directly whether active surveillance is appropriate for your specific tumour size, location, and pathology. Not every tumour qualifies. Tumours near the trachea or recurrent laryngeal nerve, those with lymph node involvement, or those in patients who cannot commit to regular ultrasound follow-up are generally not candidates for surveillance.

If surgery is recommended, it is reasonable to ask whether hemithyroidectomy is sufficient for your risk category, rather than proceeding directly to total thyroidectomy. The answer depends on tumour size, whether there is bilateral disease, and your surgeon's assessment of contralateral lobe findings.

For patients with advanced or recurrent DTC, molecular testing of the tumour is now a standard part of treatment planning at major centres. If your oncologist has not discussed molecular profiling, ask whether your tumour has been tested for BRAF, RAS, RET, and NTRK alterations, as these results can affect which systemic therapy is most appropriate.

Canadian patients in provinces with limited specialist access can request referral to a regional cancer centre. Telehealth platforms such as Maple and Telus Health can facilitate GP-to-specialist referrals but do not themselves provide thyroid oncology services. Science & Humans (scienceandhumans.com) and similar Canadian hormone-health platforms focus on metabolic and reproductive endocrinology and are not the appropriate route for thyroid cancer management.

Limitations and open questions

The NEJM review is a narrative clinical framework, not a randomized controlled trial. Its recommendations synthesize existing evidence but do not generate new outcome data. Several questions remain open.

Long-term outcomes for active surveillance beyond 10 years are still being collected. Most published surveillance cohorts come from Japan, where tumour biology and health system follow-up structures may differ from the Canadian context.

The SOGC has not issued a position statement on thyroid cancer management, and the Canadian Thyroid Association has not yet published a formal response to the NEJM 2026 review. Whether Canadian guidelines will be formally updated to reflect this framework is not yet known.

Molecular testing access remains uneven across Canada. The review assumes that clinicians can obtain tumour molecular profiles to guide advanced therapy decisions, but this assumption does not hold uniformly outside major urban cancer centres.

Finally, the review does not address cost-effectiveness in publicly funded health systems. The systemic therapies it recommends for advanced DTC, particularly Retevmo and Lenvima, carry list prices that make provincial formulary access a real barrier for some patients.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.